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Increasing duration of tamoxifen therapy improves survival in women with breast cancer but the impact of adherence to tamoxifen
on mortality is unclear. This study investigated whether women prescribed tamoxifen after surgery for breast cancer adhered to their
prescription and whether adherence influenced survival. A retrospective cohort study of all women with incident breast cancer in the
Tayside region of Scotland between 1993 and 2002 was linked to encashed prescription records to calculate adherence to
tamoxifen. Survival analysis was used to determine the effect of adherence on all-cause mortality. In all 2080 patients formed the
study cohort with 1633 (79%) prescribed tamoxifen. The median duration of use was 2.42 years (IQR¼1.04–4.89 years). Longer
duration was associated with better survival but this varied over time. The hazard ratio for mortality in relation to duration at 2.4
years was 0.85, 95% CI¼0.83–0.87. Median adherence to tamoxifen was 93% (interquartile range¼84–100%). Adherence o80%
was associated with poorer survival, hazard ratio 1.10, 95% CI¼1.001–1.21. Persistence with tamoxifen was modest with only 49%
continuing therapy for 5 years of those followed up for 5 years or more. Increased duration of tamoxifen reduces the risk of death,
although one in two women do not complete the recommended 5-year course of treatment. A significant proportion of women
have low adherence to tamoxifen and are at increased risk of death.
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Tamoxifen is an important adjuvant therapy for patients with
breast cancer (Osborne, 1998) and reduces the breast cancer
mortality rate over 15 years by 31% in women with oestrogen
receptor-positive early breast cancers. (Early Breast Cancer
Trialists’ Collaborative, 2005) Tamoxifen (20mg once daily) is
recommended for patients for 5 years adjuvant therapy (Early
Breast Cancer Trialists’ Collaborative Group, 2004) to provide
maximum benefit (Fisher et al, 1996; Stewart et al, 1996; Burstein
and Winer, 2000).
Adherence to a prescribed medication can be defined as: ‘the
extent to which a patient’s behaviour y coincides with medical or
health advice’ (McDonald et al, 2002). Non-adherence to
prescribed medication for patients with chronic conditions is a
major public health issue. The level of non-adherence reported by
studies is large, up to 50%, and many studies have shown worse
clinical outcomes associated with low adherence (DiMatteo, 2004).
The literature for tamoxifen deals with three different aspects of
adherence to medication. The first, duration of tamoxifen therapy
has an effect on disease recurrence and mortality from breast
cancer with 5 years being the recommended treatment period
(Swedish Breast Cancer Cooperative Group, 1996; Fisher et al,
2001; Yood et al, 2008). A second closely related aspect of
adherence is persistence or continuation of therapy where the
period that a patient continues to take the medication before a pre-
specified break in medication is measured. This differs from
duration in that if a patient restarts therapy after a break of the
specified length this additional use of medication is ignored.
Several recent studies have reported non-persistence with tamox-
ifen therapy. The first reported cumulative non-persistence for
tamoxifen in a cohort of 2816 women at 22.1% after 1 year and
35.2% at 3.5 years (Barron et al, 2007). The second followed 961
women over 5 years and found that 49% stopped taking their
tamoxifen before the recommended 5-year treatment period
(Owusu et al, 2008). An earlier study reported 17% of women
aged 65þ years had stopped treatment within 2 years (Fink et al,
2004). However, none of these studies assessed the impact of
failure to persist with therapy on mortality or the independent
effect of non-adherence in patients taking tamoxifen.
The last aspect of adherence to tamoxifen is whether the patients
take the medication consistently on a daily basis as prescribed. A
recent review concluded that this aspect of non-adherence to
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sadjuvant medication may limit the efficacy of breast cancer
treatment, although there was limited evidence for this (Chlebow-
ski et al, 2006). Adherence to adjuvant tamoxifen during clinical
trials is high, with reported levels of 94–100% (Fisher et al, 1994,
1996; Dewar et al, 1996). Community-based studies found that 23%
of patients failed to take tamoxifen in 1 out of 5 days with
adherence falling from 89 to 50% over 4 years (Partridge et al,
2003) and that deviations from prescribed tamoxifen therapy were
common (Demissie et al, 2001). A small survey on self reported
adherence in 53 women found that 62% acknowledged having
missed at least one dose of tamoxifen in the previous 6 months,
with 24% missing at least one dose per week (Murthy et al, 2002).
These studies suggest that non-adherence to tamoxifen is under-
estimated and further understanding of the relationship to
mortality is required. No previous study has examined the overall
effect on all-cause mortality of duration of use, adherence to and
persistence with tamoxifen either in the hospital or community
setting.
The aim of this study was to investigate adherence to
tamoxifen for all women with breast cancer drawn from a defined
geographical population in Tayside, Scotland. The objectives
were to:
Describe the duration of use, adherence to and persistence with
tamoxifen in a geographically defined population of women.
Investigate whether duration and adherence to tamoxifen
influenced all-cause mortality after adjusting for important clinical
and demographic factors.
MATERIALS AND METHODS
Identification of study cohort
Women resident in Tayside registered with the Cancer Registry as
having breast cancer or with an initial hospital admission for
breast cancer from 1993 to January 2002 were identified. Only
those women who were resident for the entire period of the study
or until death were included. Patients who had prescribing or
hospital admission records, an audit record and a Cancer Registry
record within the study period comprised the population of
interest. Every patient registered with a general practitioner in
Tayside is assigned a 10 digit unique patient identifier, the
Community Health Index number (CHI number) used in all NHS
encounters. The CHI number, which includes the patient’s date of
birth, allows linkage of health-related datasets providing a unique
resource combining information on dispensed prescribing with
detailed clinical data at the individual patient level.
Study covariates
Date of diagnosis was recorded from either the Cancer Registry or
the clinical audit records and age at diagnosis was then calculated.
Duration of breast cancer was calculated from the date of diagnosis
to the date of death or until 7 January 2002, which was the study
cutoff point. Each patient had a Carstairs score (a measure of
deprivation (Carstairs and Morris, 1990)) and subsequent category
calculated based on their home postcode using census data from
2001. There were only two patients in Carstairs category 7, the
most deprived grouping, and so categories 6 and 7 were grouped
together for analysis.
A Charlson’s co-morbidity index, which included a category for
presence of cancer, was derived for each patient using standard
procedures and the ICD codes version 9 (Deyo et al, 1992) and 10
(Sundararajan et al, 2004) in the hospital admission records. The
encashed prescribing records were also examined and the Charlson
disease groups were flagged for patients who were receiving
medication for respiratory disease, AIDS, peptic ulcers, cancer,
metastatic tumours, diabetes, myocardial infarction, connective
tissue disorders and dementia. Charlson Index scores were
calculated and categorised into three groups with low (0–2),
medium (3–5) and high morbidity (6þ). The number of different
preparations prescribed to patients’ for the 6 months prior to
diagnosis was counted and categorised into four groups, 0, 1–2,
3–5 or 6þ. The characteristics of the tumour on presentation
were recorded using clinical TNM categories (tumour size,
presence of regional node metastasis and distant metastases),
pathological grading, pathological description of axillary node
metastasis and oestrogen receptor status. Where conflicts existed
between the cancer registry and clinical audit records, the audit
records were used as the primary source of information.
Tamoxifen adherence
Each prescription for tamoxifen was analysed and the number of
days covered by that prescription recorded from the number of
dispensed tablets and daily dose. The duration of tamoxifen
therapy was calculated from the number of days between the first
and last prescription and the coverage of the last prescription. The
adherence index for each patient was calculated by: summing the
coverage for all the prescriptions for each patient, dividing it
by the duration, and then converting this to a percentage
(see Figure 1). The adherence index was calculated across the
entire duration of therapy whether this exceeded 5 years or not.
Based on the existing literature (Murthy et al, 2002; Wei et al, 2002;
Partridge et al, 2003) patients with an adherence index less than
80% were deemed to have ‘low adherence’ (Osterberg and
Blaschke, 2005).
To allow a direct comparison with previous studies, (Barron
et al, 2007) persistence was calculated as the length of time from
first prescription to a break of at least 180 days before the
completion of 5 years of therapy. Patients who continued
treatment had their length of persistence calculated using either
the date of death or the end of the study period.
Outcome variable
The main outcome measure was all-cause mortality recorded on
the General Registry Office death certificate.
Statistical analysis
Data were described as number of subjects (percentages) for
categorical variables and mean (s.d.) for continuous variables.
Where continuous variables did not follow a normal distribution,
tested using the Shapiro–Wilks test for skewness, the median and
interquartile range were reported. w
2 tests for trend (w
2 trend, d.f.,
P) were reported for differences in distribution of the population
with n categories. Cox Proportional Hazards models were utilised
to estimate hazard ratios and 95% confidence intervals for each
unadjusted and adjusted covariate for all-cause mortality. Patients
were followed up from date of diagnosis or commencement of
tamoxifen until time of death or the end of the study.
• • Individual patient has  Individual patient has encashed encashed the prescriptions below the prescriptions below
EAR342561, 12032000, 36412, Tamoxifen, 1/D, 28, Tabs, 20mg EAR342561, 12032000, 36412, Tamoxifen, 1/D, 28, Tabs, 20mg
EAR342561, 12052000, 36412, Tamoxifen, 1/D, 28, Tabs, 20mg EAR342561, 12052000, 36412, Tamoxifen, 1/D, 28, Tabs, 20mg
EAR342561, 12062000, 36412, Tamoxifen, 1/D, 28, Tabs, 20mg EAR342561, 12062000, 36412, Tamoxifen, 1/D, 28, Tabs, 20mg
EAR342561, 12082000, 36412, Tamoxifen, 1/D, 28, Tabs, 20mg EAR342561, 12082000, 36412, Tamoxifen, 1/D, 28, Tabs, 20mg
• • No of days coverage = 4×28 = 112  No of days coverage = 4×28 = 112 
• • Calculate duration of therapy from first and last  Calculate duration of therapy from first and last 
prescription prescription
• • Duration is from 12/3/2000 to 12/08/2000 + 28 days = 182 Duration is from 12/3/2000 to 12/08/2000 + 28 days = 182
• • Adherence index = (112/182)×100= 62% Adherence index = (112/182)×100= 62%
Figure 1 Calculation of adherence and duration.
Tamoxifen adherence and survival
C McCowan et al
1764
British Journal of Cancer (2008) 99(11), 1763–1768 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sMultivariable results are presented as hazard ratios and 95%
confidence intervals. Covariates were included in the multivariate
model if they were deemed to be of clinical significance or had
univariable P-value o0.2. The proportional hazards assumption
was assessed using trend-tests of the Schoenfeld residuals and
those which failed the assumption or which were deemed to be
time-dependent were entered as continuous time-dependent
covariates (Bradburn et al, 2003).
In a community-based, non-randomised study many known and
unknown factors may determine who receives tamoxifen, which
can potentially bias results. A propensity score estimating the
probability of a patient receiving tamoxifen was calculated using a
logistic regression model for age, social class, pathological tumour
characteristics, Charlson’s index and co-prescribing (Wang and
Donnan, 2001). This was added to the model to adjust for
propensity to receive tamoxifen and so reduce bias in the survival
analysis. All statistical analyses were performed using Stata
version 9.
The study was granted approval from the Tayside Committee on
Medical Research Ethics and the Caldicott Guardian.
RESULTS
A total of 2184 patients were identified with prescribing, hospital
admission records for breast cancer surgery, cancer audit and
cancer registry records for the period of the study. Patients who
were known to have had cancer before 1993, or who received
tamoxifen more than 6 months prior to their diagnosis or those
diagnosed with ductal carcinoma in situ alone were excluded. This
left a total of 2080 patients whose records were analysed within this
study. The mean age at diagnosis was 61.4 (s.d.¼14.02) and
patients were followed up for a total of 7619 person years with a
median follow-up of 3.16 years (interquartile range¼1.38–5.72
years). A total of 511 deaths (25%) were recorded.
Descriptive statistics for duration, adherence and
persistence with tamoxifen
Tamoxifen was prescribed as therapy to 1633 (79%) patients of
whom 414 (25%) died during the study. The median duration of
tamoxifen in the study was 2.42 years (interquartile range¼1.04–
4.89 years). Patients were generally highly adherent to their
medication during the course of treatment with a median
adherence of 93% (interquartile range¼84–100%). There were
315 (19%) patients with low adherence of less than 80%. There was
no difference in low adherence by social class (P¼0.96) but there
was a trend for a higher proportion of younger women to have low
adherence (Po0.001).
However, 411 (33%) patients prescribed tamoxifen discontinued
their medication before completing 5 years of treatment. Within 1
year of commencing tamoxifen 10% of patients had discontinued
treatment, for patients followed for 2 years or more 19% patients
had discontinued treatment, 32% patients for those followed for
three and a half years or more and 51% patients of those followed
for 5 years plus.
Comparison of tamoxifen users and non users
The distribution of age, social class, Charlson’s index and
co-prescribing is presented in Table 1. Women in the younger
age groups were less likely to receive tamoxifen than older patients
(Po0.001); social class categories 2 and 3 had the highest
proportion of women not receiving the drug (P¼0.011)
and patients who received tamoxifen had higher levels of
co-prescribing (Po0.001) and greater Charlson’s Index scores
(Po0.001).
Patient characteristics and tamoxifen usage
The clinical and pathological characteristics of the cancer at
diagnosis are shown in Table 2. There were no differences in
clinical tumour stage (P¼0.86) between tamoxifen users and those
who did not receive the drug. However, patients were less likely to
receive tamoxifen therapy if they had positive clinical nodes at
initial diagnosis (P¼0.001), if metastases were present (P¼0.03);
if tumour grade was worse (Po0.001), if patients had positive
nodes on pathology (Po0.001) or if they had negative oestrogen
receptor status (Po0.001).
Cox proportional hazards model for all-cause mortality
An initial multivariate model was created to investigate the effect
of tamoxifen use and showed that patients not prescribed
tamoxifen were at significantly higher risk of death than patients
who were prescribed tamoxifen after allowing for all other
covariates (HR¼1.36, 95% CI¼1.05–1.76).
A subsequent multivariate model investigated the adjusted effect
of covariates for those patients who used tamoxifen. Adjusting for
all factors, increasing age, increasing tumour grade, positive or
unknown pathological node status and negative or unknown
oestrogen receptor status increased the risk of death. A Charlson’s
Index score of 6 or more also increased the risk of death over time,
at the median duration of 2.4 years, the hazard ratio increased by
1.59, 95% CI¼1.14–2.21. Duration of tamoxifen use was also
associated with better survival after allowing for other covariates
and the hazard ratio at a given time could be calculated using the
equation HR¼exp( 0.065   follow-up time). At 2.4 years, the
median duration, the hazard ratio was 0.85, 95% CI¼0.83–0.87
(see Table 3).
Patients with an adherence index of o80% had an increased
hazard of death calculated using the equation HR¼exp(0.04  
Table 1 Descriptive statistics of cohort- age, social class, Charlson’s
index and co-prescribing
Patients with
tamoxifen (%)
No tamoxifen
(%)
Wald v
2 test
(Wald, d.f., P)
Numbers 1633 (79) 447 (21)
Age group
o40 84 (5) 37 (8) 22.6, 5, Po0.001
40–49 237 (15) 94 (21)
50–59 435 (27) 112 (25)
60–69 365 (22) 95 (21)
70–79 331 (20) 77 (17)
80+ 181 (11) 32 (7)
Carstairs category
1 152 (9) 29 (7) 14.9, 5, P¼0.011
2 327 (20) 108 (24)
3 443 (27) 145 (32)
4 306 (19) 66 (15)
5 164 (10) 34 (8)
6/7 237 (15) 64 (14)
Number of prescriptions at diagnosis
0 500 (31) 254 (57) 104.9, 3, Po0.001
1–2 457 (28) 77 (17)
3–5 397 (24) 63 (14)
6+ 279 (17) 53 (12)
Charlson’s index
0–2 476 (29) 198 (44) 37.9, 2, Po0.001
3–5 510 (31) 100 (22)
6+ 647 (40) 149 (33)
Tamoxifen adherence and survival
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sfollow-up time). At the median duration of tamoxifen use of 2.4
years the hazard ratio for low adherence was 1.10, 95% CI¼1.001–
1.21 (Table 3).
Tamoxifen is not recommended for use in patients with
oestrogen receptor negative tumours, although within our study
population it was used with this patient group. Restricting the
analysis to patients with ER þve or ER status unknown was
associated with a significantly increased hazard of death for
adherence below 80%, HR¼exp(0.05   follow-up time), 95% CI
0.01–0.10, the hazard ratio at the median duration being 1.13, 95%
CI¼1.01–1.26.
DISCUSSION
This study suggests that adherence to taking daily tamoxifen in the
community setting is high, over four-fifths of women prescribed
tamoxifen had an adherence of 80% or above during the course of
treatment. However, cumulative persistence with tamoxifen
treatment is low, with 51% of the patient population followed for
5 years or more discontinuing treatment by 5 years. The study
defined high adherence at 80% or over and there was a significant
increase in hazard of death for patients with adherence beneath
that level. This suggests that the longer a patient has low adherence
the greater their increase in hazard of death. Patients who were
prescribed tamoxifen had better survival after adjusting for other
factors than those who did not, and the duration of tamoxifen use
was also seen to reduce the hazard of death.
This study supports the use of tamoxifen in the community
setting as an adjuvant therapy that reduces mortality in women
with breast cancer. Though the reduction in hazard in this
community-based study is lower, the higher survival figures
reported in randomised controlled trials may reflect different
inclusion criteria or some selection bias in terms of recruiting
‘healthier’ patients with less co-morbid illness to these trials.
In terms of generalisability, the study population comprised of
women who had an initial attendance at a hospital for breast
cancer, had an accompanying cancer registry record entry and a
history of prescribing. The women also needed to be resident in
the region served by the breast cancer service for the entire study
period or until death to ensure that there was no loss to follow-up.
Thus the study cohort of 2184 women accounts for 85% of
potential patients.
Around three-quarters of breast cancer patients in Tayside
received tamoxifen as adjuvant therapy, as reported elsewhere
(Demissie et al, 2001). Approximately one-fifth of tamoxifen users
had adherence below 80% similar to studies elsewhere (Murthy
et al, 2002; Partridge et al, 2003). Non-persistence with tamoxifen
therapy at 1 year differed from the figure reported in the study by
Barron et al (2007) but at three and a half years was at a similar
Table 2 Clinical and pathological characteristics of cancer at initial
diagnosis
Patients with tamoxifen
(%)
No tamoxifen
(%)
Wald v
2 test
(Wald, d.f., P)
Numbers 1633 (79) 447 (21)
Tumour stage
1 440 (27) 119 (27) 1.3, 4, P¼0.86
2 522 (32) 136 (30)
3 118 (7) 36 (8)
4 141 (9) 35 (8)
Unknown 412 (25) 121 (27)
Clinical nodes
0 1144 (70) 316 (71) 17.7, 3, P¼0.001
1 230 (14) 74 (17)
2 34 (2) 20 (4)
Unknown 225 (14) 37 (8)
Clinical metastases
No 1354 (83) 365 (82) 7.1, 2, P¼0.03
Yes 72 (4) 33 (7)
Unknown 207 (13) 49 (11)
Tumour grade
1 221 (14) 48 (11) 86.7, 3, Po0.001
2 545 (33) 128 (29)
3 363 (22) 194 (43)
Unknown 504 (31) 77 (17)
Oestrogen receptor status
Positive 869 (53) 142 (32) 227.1, 2,
Po0.001
Negative 199 (12) 195 (43)
Unknown 565 (35) 110 (25)
Pathological nodes
Negative 754 (46) 230 (52) 16.4, 2, Po0.001
Positive 446 (27) 140 (31)
Unknown 433 (27) 77 (17)
Table 3 Multivariate association between covariates and all cause
mortality
Adjusted for other covariates
Predictor HR 95% CI
Age (10 years) 1.15 1.05–1.27 P¼0.004
Carstairs category
1 (most affluent) 1.0
2 0.86 0.56–1.32 P¼0.486
3 1.03 0.69–1.54 P¼0.878
4 1.23 0.81–1.86 P¼0.333
5 1.04 0.66–1.65 P¼0.851
6/7 (most deprived) 1.27 0.82–1.97 P¼0.353
Charlson’s index (at 2.4 years)
0–2 1.0
3–5 1.21 0.83–1.78 P¼0.325
6+ 1.59 1.14–2.21 P¼0.006
Number of prescriptions at diagnosis
0 1.0
1–2 0.75 0.46–1.23 P¼0.253
3–5 0.56 0.22–1.22 P¼0.143
6+ 0.44 0.16–1.18 P¼0.104
Tumour grade
1
2 2.49 1.24–4.98 P¼0.010
3 4.03 2.01–8.08 Po0.001
Unknown 2.22 0.89–5.54 P¼0.089
Oestrogen receptor status
Positive 1.0
Negative 1.96 1.46–2.62 Po0.001
Unknown 1.47 1.10–1.97 P¼0.009
Pathological nodes
Negative 1.0
Positive 2.05 1.54–2.72 Po0.001
Unknown 2.19 1.57–3.04 Po0.001
Propensity score 0.01 0.00–3.30 P¼0.106
Duration of tamoxifen (at 2.4 years) 0.85 0.83–0.87 Po0.001
Adherence o80% (at 2.4 years) 1.10 1.001–1.21 P¼0.046
Tamoxifen adherence and survival
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slevel and was similar to the figure reported by Fink et al (2004) at 2
years and Owusu et al (2008) at 5 years. Hence, the characteristics
of tamoxifen use, adherence and persistence in this population is
similar to those from other published work. This study concen-
trated on the duration of tamoxifen use and adherence to taking it
on a prescribed daily basis, as this is a more complete marker of
use than non-persistence. What is added to the existing literature
is the linkage between low adherence and increased all-cause
mortality.
The use of the propensity score within the final model helps
reduce potential selection bias (Wang and Donnan, 2001) because
of the use of observational data, where clinicians may choose
patients with a lower risk of mortality to receive tamoxifen.
However, our analysis holds after allowing for the predisposition
of a patient to receive tamoxifen. With 79% of patients receiving
tamoxifen it is unlikely that they were selected as having better
survival prospects.
In terms of potential shortcomings, this study measured the
adherence to medication by looking at the encashment of
prescriptions. Although there are advantages and disadvantages
to various techniques for measuring adherence, (Osterberg and
Blaschke, 2005) and whereas we cannot tell if patients actually took
the medication, breast cancer patients are probably motivated to
be adherent, as reflected in the high levels of adherence reported
by this and other studies. Tayside has a closed pharmacy system as
all encashed prescriptions are returned to a central government
office for reimbursement and this allowed us to measure adherence
objectively across the whole population.
There was approximately 1 in 5 patients with less than 80%
adherence, which means this study had low power to determine if
adherence has an effect on mortality. In addition, it is now
appreciated that ER-negative patients (200 in this study) do not
benefit from adjuvant tamoxifen and would also reduce power.
The study aimed to look at the effect of adherence to tamoxifen on
survival in a broad range of women with breast cancer-prescribed
tamoxifen in the community. Consequently, we included patients
in the study cohort who would not have been eligible for inclusion
in trials or where current treatment guidelines would not
recommend its use. There were 105 patients with clinical
metastases who received tamoxifen and such women may have
had a different motivation to take their medication than those
receiving it as adjuvant therapy. As the aim of our study was to
assess the effect of adherence to tamoxifen in the community,
using a comprehensive prescribing dataset to monitor long-term
adherence, we intentionally included both patients with clinical
metastases and also patients who were ER negative in our analysis.
The effect of adherence to tamoxifen on survival was still evident
in subsequent analysis performed on the cohort with these patient
groups excluded.
This study could not explain why some women were not
adherent to or discontinued their medication, although it
suggested younger women were more likely to have low adherence.
Other work agrees with this finding and also suggests side effects
or a perception of low benefits from taking medication leads to
lower adherence in younger women (Fink et al, 2004; Grunfeld
et al, 2005; Chlebowski et al, 2006).
The study did not report on chemotherapy or radiotherapy use.
Treatment in Tayside used standard practises for both treatments
over the study period so it seems unlikely that there could be any
systematic difference in chemotherapy or radiotherapy use
between any of the groups of interest. Furthermore, radiotherapy
affects mortality only after 10–15 years so it would not have been a
factor within our analysis (Clarke et al, 2005).
Recurrence of breast cancer was also omitted because of the
difficulties in ascertaining recurrence within a community setting.
The routine datasets used do not record cancer recurrences
directly and so a proxy measure would have been required which
we decided against. Although this would not affect the main
outcome of mortality we may have overestimated the number of
women who discontinue their medication.
Lastly, the outcome used within the study was all-cause
mortality selected as the accurate recording of cause of death has
been questioned in the literature (Clark et al, 2003).
This study confirms that around 20% of patients have an
adherence level, o80%, the equivalent of missing at least one
tablet every 5 days. Our findings suggest that adherence to
tamoxifen beneath this level has a negative effect on survival. The
relatively long half-life of tamoxifen (Osborne, 1998) may mean
that missing an occasional tablet is less of an issue and that the
patients will still benefit from tamoxifen therapy. Aromatase
inhibitors are increasingly used as adjuvant therapy but have a
shorter half-life than tamoxifen and so strict adherence to this
medication regimen should be emphasised as the occasional
missed dose may have a greater detrimental effect on survival.
CONCLUSION
Patients who are prescribed adjuvant tamoxifen in the community
have a lower risk of death with increased duration of use further
reducing the risk. Cumulative non-persistence with tamoxifen
therapy occurs in nearly half of patients prescribed tamoxifen.
Conversely, in those who continue to take tamoxifen adherence is
generally high, but there is a significant proportion of women
with low adherence who are at greater risk of death. Patients
need to be encouraged to continue their medication for the full
5-year recommended period to ensure their best chance of
survival.
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